Is Semax safe during pregnancy or breastfeeding?

Semax, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the regulatory status of Semax?

Semax regulatory status: Unapproved (approved in Russia) in the United States; WADA status not on prohibited list; research level multi-decade russian clinical use. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the evidence base for Semax?

Semax's evidence base sits at multi-decade russian clinical use. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How long until I see results from Semax?

Acute effects from Semax appear within hours of dosing for receptor-level changes. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

How does Semax's half-life affect dosing?

Semax has a plasma half-life of CNS effect hours; plasma minutes, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 2-4x daily for 10-14 day courses dosing at 300-2000 mcg per dose (varies) per dose explains the typical onset timeline for scheduling and cycle endpoints.

What are the safety considerations for Semax?

Excellent tolerability. Mild nasal irritation possible. No dependence. For scheduling and cycle use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Semax's CNS effect hours; plasma minutes pharmacokinetic profile and intranasal administration route influence the side-effect profile in predictable ways.

Home/ Compounds/ Semax

Semax

Protocol

Scheduling Semax alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.

Protocol / Scheduling / Cycling Applications

Protocol CalendarOff-TimeLoading PhasePulse StrategiesWash-Out

Key Takeaways

Scheduling lens: Semax's CNS effect hours; plasma minutes half-life via intranasal places it in the multi-daily-dosing bucket.
Mechanism: Elevates BDNF and NGF in hippocampus and cortex.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Elevates BDNF and NGF in hippocampus and cortex. Modulates dopamine and serotonin transporter expression. Inhibits enkephalinase, indirectly extending endogenous enkephalin action. Approved in Russia for stroke rehabilitation and cognitive disorders. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Semax.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Semax protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Semax schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

Semax with a CNS effect hours; plasma minutes half-life pharmacokinetic profile sits in the multiple-daily-dosing bucket. The schedule is best built around either 2-4x daily for 10-14 day courses, with consistency mattering more than the absolute clock time of any single dose.

Cycle length and off-cycle planning

Standard Semax cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Protocol / Scheduling / Cycling Applications

Weekly Timing

The most-asked scheduling question for Semax in weekly timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Multi-Peptide Timing

Schedule design for Semax in multi-peptide timing starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Stack Scheduling

For stack scheduling scheduling, Semax is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Pulse Strategies

The most-asked scheduling question for Semax in pulse strategies is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300-2000 mcg per dose (varies)	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180-2000 mcg per dose (varies)	4–6 weeks initial cycle
Protocol focus	Intranasal	300-2000 mcg per dose (varies)	2-4x daily for 10-14 day courses
Maintenance phase	Intranasal	210-2000 mcg per dose (varies)	Ongoing with periodic pauses

Dose timing for Semax is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Semax stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Semax + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Semax's mechanism in protocol / scheduling / cycling protocols.
Semax + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Semax's mechanism in protocol / scheduling / cycling protocols.
Semax + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Semax's mechanism in protocol / scheduling / cycling protocols.
Semax + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Semax's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (approved in Russia) Research: Multi-decade Russian clinical use

Excellent tolerability. Mild nasal irritation possible. No dependence.

Lens-specific safety considerations for protocol / scheduling / cycling use of Semax: Excellent tolerability. Mild nasal irritation possible. No dependence. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Semax — neuroprotective effects

PMID 8941050

Supporting

Semax in ischemic stroke recovery

PMID 21643748

Semax vs Related Peptides

Compound	Profile	Onset	Best For
Semax	ACTH-derived nootropic heptapeptide	CNS effect hours; plasma minutes	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Daily timing for Semax?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

Cycle length and off-cycle period?

Standard cycle for Semax is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

What is Semax?

Semax (also known as Pro-Gly-Pro-ACTH(4-10) / MEHFPGP) is a 7-residue acth-derived nootropic heptapeptide with a molecular weight of 813 Da and a plasma half-life of CNS effect hours; plasma minutes. Elevates BDNF and NGF in hippocampus and cortex. Modulates dopamine and serotonin transporter expression. Inhibits enkephalinase, indirectly extending endogenous enkephalin action. Approved in Russia for stroke rehabilitation and cognitive disorders. The compound is studied primarily in the protocol / scheduling / cycling domain for the applications outlined above.

How do I schedule Semax alongside my existing stack?

Semax's schedule is built around its CNS effect hours; plasma minutes pharmacokinetics and 2-4x daily for 10-14 day courses dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

Clinical Protocol

Start a Semax Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Semax and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 813 Da
Sequence length: 7 aa
Half-life: CNS effect hours; plasma minutes
WADA: Not on prohibited list
FDA: Unapproved (approved in Russia)
Research: Multi-decade Russian clinical use

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semax unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Semax

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised